Evidence map›Paper›PMID 38893256›Full record

ArticleCancers2024

Prognostic Impact and Clinical Implications of Adverse Tumor Grade in Very Favorable Low- and Intermediate-Risk Prostate Cancer Patients Treated with Robot-Assisted Radical Prostatectomy: Experience of a Single Tertiary Referral Center.

Antonio Benito Porcaro, Alberto Bianchi, Sebastian Gallina, Andrea Panunzio, Alessandro Tafuri, Emanuele Serafin, Rossella Orlando, Giovanni Mazzucato, Paola Irene Ornaghi, Francesco Cianflone and 9 more

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Antonio Benito PorcaroDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.ORCID 0000-0002-7890-040X
Alberto BianchiDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.
Sebastian GallinaDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.
Andrea PanunzioDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.ORCID 0000-0002-9756-4632
Alessandro TafuriDepartment of Urology, Vito Fazzi Hospital, 73110 Lecce, Italy.
Emanuele SerafinDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.ORCID 0000-0002-5646-9719
Rossella OrlandoDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.
Giovanni MazzucatoDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.
Paola Irene OrnaghiDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.
Francesco CianfloneDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.
Francesca MontanaroDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.
Francesco ArtoniDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.
Alberto BaielliDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.
Francesco DitonnoDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.
Filippo MiglioriniDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.
Matteo BrunelliDepartment of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.
Salvatore SiracusanoDepartment of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Maria Angela CerrutoDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.
Alessandro AntonelliDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37129 Verona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess the prognostic impact and predictors of adverse tumor grade in very favorable low- and intermediate-risk prostate cancer (PCa) patients treated with robot-assisted radical prostatectomy (RARP).

methodsData of low- and intermediate PCa risk-class patients were retrieved from a prospectively maintained institutional database. Adverse tumor grade was defined as pathology ISUP grade group > 2. Disease progression was defined as a biochemical recurrence event and/or local recurrence and/or distant metastases. Associations were assessed by Cox's proportional hazards and logistic regression model.

resultsBetween January 2013 and October 2020, the study evaluated a population of 289 patients, including 178 low-risk cases (61.1%) and 111 intermediate-risk subjects (38.4%); unfavorable tumor grade was detected in 82 cases (28.4%). PCa progression, which occurred in 29 patients (10%), was independently predicted by adverse tumor grade and biopsy ISUP grade group 2, with the former showing stronger associations (hazard ratio, HR = 4.478; 95% CI: 1.840-10.895;

conclusionsIn a very favorable PCa patient population, adverse tumor grade was an unfavorable prognostic factor for disease progression. Active surveillance in very favorable intermediate-risk patients is still a hazard, so molecular and genetic testing of biopsy specimens is needed.

Indexed as

adverse pathology outcomesintermediate-risk prostate cancerlow-risk prostate cancerprogression of prostate cancerprostate cancerrobot-assisted radical prostatectomy (RARP)tumor upgradingtumor upstaging

Identifiers

PMID38893256
PMCPMC11171498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.